MedPath
HSA Approval

Sunlenca film-coated tablet 300mg

SIN17188P

Sunlenca film-coated tablet 300mg

Sunlenca film-coated tablet 300mg

February 27, 2025

GILEAD SCIENCES SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGILEAD SCIENCES SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

J05AX31

Manufacturer Information

GILEAD SCIENCES SINGAPORE PTE. LTD.

Rottendorf Pharma GmbH

Esteve Quimica S.A.

Active Ingredients

Lenacapavir Sodium eqv Lenacapavir

300mg

Lenacapavir

Documents

Package Inserts

SUNLENCA TAB PI.pdf

Approved: February 27, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.